Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting an...

Industry: Biotechnology
Sector: Healthcare
Phone: 416-964-5442
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
DIJG
DIJG Aug. 19 at 1:55 PM
$MDNAF Huge news out today from Merck/Moderna. Cancer vaccine is great news for patient. It is important to note that the cancer vaccine is for neo-adjuvent setting while MDNA11 is in Advanced/Metastatic disease setting both drugs are not competing
0 · Reply
rudazur2
rudazur2 Aug. 19 at 11:22 AM
$MDNAF bad news for us with moderna and merck succes in ph3
2 · Reply
Lytnup
Lytnup Aug. 18 at 4:16 AM
$MDNAF And another one https://substack.com/@david132748/note/p-211573009?r=10wt7d&utm_medium=ios&utm_source=notes-share-action https://substack.com/@david132748/note/p-211576131?r=10wt7d&utm_medium=ios&utm_source=notes-share-action
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 17 at 2:07 AM
$MDNAF
0 · Reply
steven1x
steven1x Aug. 16 at 6:20 PM
$MDNAF timeframe? https://g.co/gemini/share/336ed2250bb0
0 · Reply
Lytnup
Lytnup Aug. 14 at 9:51 PM
$MDNAF In case anyone else besides me doesn’t have anything better to do, I would recommend David’s latest Investment Summary (over an hour and a half, with lots of information), along with the updated August 2026 Slide Deck (which shows Dr. Ascierto as Chair of MDNAs Clinical Advisory Board, and Dr. Ibrahim as CMO - no longer fractional?) https://substack.com/@david132748/note/p-211080994?r=10wt7d&utm_medium=ios&utm_source=notes-share-action https://ir.medicenna.com/static-files/f4748b19-5500-4d9e-b2d4-0c08830b627c
1 · Reply
rudazur2
rudazur2 Aug. 14 at 7:40 PM
$MDNAF great volume lets see if we close red as usual 🤣
1 · Reply
boomshiva
boomshiva Aug. 14 at 6:36 PM
$MDNAF wdf? I'm not complaining, I just want to understand what's driving this and if it'll disappear come Monday morning.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 14 at 5:54 PM
$MDNAF Pretty impressive that this is our guy! If he believes… https://oncodaily.com/career/paolo-ascierto
1 · Reply
DIJG
DIJG Aug. 14 at 1:41 PM
$MDNAF Absolutely huge news this morning. Medicenna has now confirmed it will pursue Accelerated Approval (AA) pathways — exactly what we’ve been expecting. Like i previously stated, If Replimune, with its flawed trial design, secured AA, it’s almost unthinkable that ABILITY‑1 — with better efficacy, cleaner safety, and a superior study design — wouldn’t produce two AA‑eligible candidates, including melanoma. Based on Medicenna past attendance, The major oncology conference remaining for 2026 are: SITC and ESMO and two oral sessions coming-That’s massive. Oral sessions are extremely competitive and reserved for serious, high‑value readouts. For reference, The December 2025 MDNA11 data was strong, yet it only earned a poster at ESMO. Now that the program has been upgraded to oral. That tells you everything. You can draw your own conclusions. MDNA11 stepping into oral territory signals one thing: The data is getting harder to ignore.
1 · Reply
Latest News on MDNAF
No data available.
DIJG
DIJG Aug. 19 at 1:55 PM
$MDNAF Huge news out today from Merck/Moderna. Cancer vaccine is great news for patient. It is important to note that the cancer vaccine is for neo-adjuvent setting while MDNA11 is in Advanced/Metastatic disease setting both drugs are not competing
0 · Reply
rudazur2
rudazur2 Aug. 19 at 11:22 AM
$MDNAF bad news for us with moderna and merck succes in ph3
2 · Reply
Lytnup
Lytnup Aug. 18 at 4:16 AM
$MDNAF And another one https://substack.com/@david132748/note/p-211573009?r=10wt7d&utm_medium=ios&utm_source=notes-share-action https://substack.com/@david132748/note/p-211576131?r=10wt7d&utm_medium=ios&utm_source=notes-share-action
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 17 at 2:07 AM
$MDNAF
0 · Reply
steven1x
steven1x Aug. 16 at 6:20 PM
$MDNAF timeframe? https://g.co/gemini/share/336ed2250bb0
0 · Reply
Lytnup
Lytnup Aug. 14 at 9:51 PM
$MDNAF In case anyone else besides me doesn’t have anything better to do, I would recommend David’s latest Investment Summary (over an hour and a half, with lots of information), along with the updated August 2026 Slide Deck (which shows Dr. Ascierto as Chair of MDNAs Clinical Advisory Board, and Dr. Ibrahim as CMO - no longer fractional?) https://substack.com/@david132748/note/p-211080994?r=10wt7d&utm_medium=ios&utm_source=notes-share-action https://ir.medicenna.com/static-files/f4748b19-5500-4d9e-b2d4-0c08830b627c
1 · Reply
rudazur2
rudazur2 Aug. 14 at 7:40 PM
$MDNAF great volume lets see if we close red as usual 🤣
1 · Reply
boomshiva
boomshiva Aug. 14 at 6:36 PM
$MDNAF wdf? I'm not complaining, I just want to understand what's driving this and if it'll disappear come Monday morning.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 14 at 5:54 PM
$MDNAF Pretty impressive that this is our guy! If he believes… https://oncodaily.com/career/paolo-ascierto
1 · Reply
DIJG
DIJG Aug. 14 at 1:41 PM
$MDNAF Absolutely huge news this morning. Medicenna has now confirmed it will pursue Accelerated Approval (AA) pathways — exactly what we’ve been expecting. Like i previously stated, If Replimune, with its flawed trial design, secured AA, it’s almost unthinkable that ABILITY‑1 — with better efficacy, cleaner safety, and a superior study design — wouldn’t produce two AA‑eligible candidates, including melanoma. Based on Medicenna past attendance, The major oncology conference remaining for 2026 are: SITC and ESMO and two oral sessions coming-That’s massive. Oral sessions are extremely competitive and reserved for serious, high‑value readouts. For reference, The December 2025 MDNA11 data was strong, yet it only earned a poster at ESMO. Now that the program has been upgraded to oral. That tells you everything. You can draw your own conclusions. MDNA11 stepping into oral territory signals one thing: The data is getting harder to ignore.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 14 at 12:28 PM
$MDNAF Atleast we have a timeline, sort of. An “Oral Presentation “ is an extremely positive sign. If the meeting is at SITC in November then the data must look pretty good!
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 14 at 12:26 PM
$MDNAF https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-first-quarter-fiscal-2027
0 · Reply
rudazur2
rudazur2 Aug. 13 at 2:26 PM
$MDNAF can we just go back to 0.6$ like that I can exit ? 😂😂
2 · Reply
DIJG
DIJG Aug. 13 at 1:55 PM
$MDNAF Some people think ABILITY‑1 no longer matters due to NEO‑CYT-that’s not true. For now, ABILITY‑1 is MDNA’s core trial and the foundation for any future approval. The FDA does not approve neoadjuvant immunotherapies without prior metastatic approval, so ABILITY‑1 must come first before MDNA can earn a neoadjuvant label, a company‑sponsored trial with 300+ patients using EFS or FRS—the actual approval endpoints. The current NEO‑CYT measures MPR, a strong biological signal, but MPR is not an Approval endpoint like FRS & EFS. And because NEO‑CYT is investigator‑led not company-led, regulators will not accept it as standalone approval data. Its purpose is to support, not replace, ABILITY‑1. ABILITY‑1 shows that MDNA11 works. NEO‑CYT shows how it works. Together, they provide powerful clinical &mechanistic evidence that MDNA11 is not another me‑too IL‑2. NEO‑CYT is a strategic deal sweetener that de‑risks MDNA11, MDNA113, and the entire superkine platform.
0 · Reply
Lytnup
Lytnup Aug. 10 at 9:55 PM
$MDNAF David’s latest offering underscores the investment thesis here nicely; would be nice if the industry in fact is moving this way. https://substack.com/@david132748/note/p-210245467?r=10wt7d&utm_medium=ios&utm_source=notes-share-action
0 · Reply
DIJG
DIJG Aug. 7 at 7:16 PM
$MDNAF Big pharma pays for clinical data, not share price. Their acquisition models are built on risk‑adjusted Net Present Value, not market cap. What matters to them is whether a drug can generate real, durable clinical benefit—and whether that benefit can be reproduced at scale. Ability‑1 has already delivered strong signals, but large pharma needs confirmation that these results aren’t a statistical fluke. That’s the purpose of the expanded cohort with readout in H2. If the data hold, MDNA won’t just be another small biotech with a promising molecule—it becomes the goose that lays the golden egg, a late‑stage immunotherapy asset with validated biology and multiple registrational paths. The stock would re-rate accordingly with very high chances of being acquired
1 · Reply
DIJG
DIJG Aug. 7 at 4:22 PM
$MDNAF Today the FDA approved Replimune's drug via the Accelerated Approval ( AA) route based on phase 1/2 data. Replimune’s AA is not just their win—it’s Medicenna’s regulatory green light. If MDNA11’s next dataset matches what has already been reported, the company leaps into • A late stage immunotherapy platform and a top tier acquisition target that big pharma cannot ignore due to having atleast two AA ready programs • A late stage immunotherapy platform with multiple registrational paths
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 6 at 12:09 PM
$MDNAF Sucks they are leaps ahead of us but if they are successful it could actually really help us in the end with early approval, maybe even off ph1/2 data, as our SE profile will be better based on the NHP data, the market seems to forget that 113 achieved >30-fold higher exposure than the α-biased comparator they used!
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 6 at 12:04 PM
$MDNAF Takeda’s IBI363 starts Ph3 today which really validates MDNA113 and the IL-2 program . They got good efficacy in PH2 but with high TREA (like 60% gr3!) hopefully that is because they are alpha based and 113 won’t show the same side effects.
1 · Reply
boomshiva
boomshiva Aug. 5 at 3:29 PM
$MDNAF Is Canada on a holiday again?
3 · Reply
boomshiva
boomshiva Aug. 3 at 5:03 PM
$MDNAF What's up here? I'm not finding anything SP moving in the usual places.
1 · Reply
Witzorwitzout1
Witzorwitzout1 Aug. 1 at 12:28 AM
$MDNAF when can we expect news from that nice Italian group doing the trial
1 · Reply